Abstract

IntroductionMajor histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. However, the function of MHC class I chain-related B (MICB) molecule is not very clear. In this study, we explored the prognostic effect of MICB in colorectal cancer.Material and methodsFrom 2008-05 to 2012-11, consecutive CRC patients of Zhongshan Hospital, Fudan University were retrospectively enrolled as primary cohort. The inclusion criteria were as follows: receiving primary radical resection, pathologically confirmed colorectal adenocarcinoma, no treatment before surgery, clinicopathological data available. Another cohort of CRC patients were collected from a public dataset GSE39582 of GEO database from 1987 to 2007 in the same criteria for validation. MICB was detected using immunochemistry and evaluated as prognostic biomarker. The cut-off value of MICB expression was calculated using X-tile software.ResultsFinally, 863 patients were enrolled in the primary cohort, and 556 patients were enrolled in the validation cohort. MICB expression was significantly associated with tumor size and primary histological type in primary cohort, and with primary tumor location and distant metastases in validation cohort. The survival analysis showed that patients with high MICB expression had significantly better overall survival in both primary (P = 0.002) and validation (P = 0.001) cohorts. The multivariate analysis also confirmed that high MICB expression was a significantly independent protective factor for overall survival in both primary (hazard ratio HR = 0.741, 95% CI 0.594–0.924) and validation (HR = 0.699, 95% CI 0.508–0.961) cohorts.ConclusionFor stage I–IV CRC patients, MICB was confirmed a novel independent prognostic factor. It could help better stratification of CRC prognosis.

Highlights

  • Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity

  • CRC cancer stages were determined according to the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) TNM classification 8th edition

  • 863 CRC patients from Zhongshan hospital, Fudan University were enrolled as primary cohort

Read more

Summary

Introduction

Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. The inclusion criteria were as follows: receiving primary radical resection, pathologically confirmed colorectal adenocarcinoma, no treatment before surgery, clinicopathological data available Another cohort of CRC patients were collected from a public dataset GSE39582 of GEO database from 1987 to 2007 in the same criteria for validation. The multivariate analysis confirmed that high MICB expression was a significantly independent protective factor for overall survival in both primary (hazard ratio HR = 0.741, 95% CI 0.594–0.924) and validation (HR = 0.699, 95% CI 0.508–0.961) cohorts. Immune surveillance can eliminate cancer cells in human body This process is closely related to major histocompatibility complex and its associated molecules. MICB is expressed by the intestinal epithelium and epithelial tumors as well (Groh et al 1999)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call